Comparative Pharmacology
Head-to-head clinical analysis: ACTIDIL versus CLARINEX D 12 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIDIL versus CLARINEX D 12 HOUR.
ACTIDIL vs CLARINEX-D 12 HOUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.
Desloratadine is a long-acting tricyclic histamine antagonist selective for H1-receptor with additional anti-inflammatory properties. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors.
2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.
1 tablet (5 mg desloratadine / 120 mg pseudoephedrine) orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
Desloratadine: 27 hours (terminal), allows once-daily dosing; pseudoephedrine: 4-6 hours (prolonged in alkaline urine).
Renal excretion of unchanged drug and metabolites accounts for approximately 60-80% of the administered dose; biliary/fecal elimination comprises the remainder (20-40%).
Desloratadine: 40.2% renal (unchanged and metabolites), 41.7% fecal; pseudoephedrine: 70-90% renal (unchanged).
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination